RNAi Therapeutics: Are They Back On Big Pharma's Radar Screen?
It certainly has been a wild ride for RNA interference (RNAi), a unique class of therapeutics believed to be the next wave of novel medicines. From the initial euphoria about the technology with its huge potential for the development of targeted therapeutics for cancer and other diseases, we have witnessed a reality check in recent years as serious challenges began to surface related to the problems of finding effective delivery of these constructs to their intended targets.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST